Madrigal Pharmaceuticals: Pioneering the NASH Drug Market with High Growth and High Stakes
Overview
Madrigal Pharmaceuticals is a clinical-stage biopharma recently transitioned to commercial status, specialized in treatments for NASH/MASH—a progressive liver disease with high unmet need. Its lead product, Rezdiffra (resmetirom), is a first-in-class therapy and, as of March 2024, is the first and only drug FDA-approved and commercially launched for this indication. Approximately 1.5 million U.S. patients are diagnosed with MASH/MASH, and 315,000 are currently treatable by specialists (the company’s initial market). Madrigal’s breakthrough status, with accelerated approval and rollout, targets a multi-billion-dollar market and positions the firm as a pioneer—and key beneficiary—of the transition as NASH therapy becomes routine. With a significant first-mover advantage and a growing patient base, Madrigal has established itself as a leading innovator in this space.